Ability Of ([18F]-AV-45) PET Scan to Distinguish Alzheimer's Disease Subjects From Cognitively Normal Individuals
| Status: | Archived |
|---|---|
| Conditions: | Alzheimer Disease |
| Therapuetic Areas: | Neurology |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 7/1/2011 |
| Start Date: | March 2009 |
| End Date: | March 2011 |
Evaluation of the Ability of a Novel [18F] Amyloid Ligand ([18F]-AV-45) to Distinguish Patients With a Clinical Diagnosis of Alzheimer's Disease From Cognitively Normal Elderly Individuals
This study will evaluate the performance characteristics of a novel [18F] amyloid detection
ligand (18F]-AV-45) with respect to its ability to distinguish patients with
clinically-diagnosed probable Alzheimer's disease from cognitively normal elderly subjects
and to independently compare its diagnostic performance characteristics with the ability of
[11C]PIB to correctly categorize the same subjects.
SPECIFIC HYPOTHESES
1. Individuals with a clinical diagnosis of probable Alzheimer's disease will have
increased brain retention of [18F]-AV-45 compared to cognitively normal elderly
individuals.
2. There will be no clinically meaningful difference in the amyloid retention performance
characteristics of [18F]-AV-45 and [l1C]PIB.
15 patients with a clinical diagnosis of probable Alzheimer's disease and 15 cognitively
normal elderly control subjects will receive both [18F]-AV-45 and [11C]PIB to compare the
diagnostic performance characteristics of each amyloid ligand to distinguish AD from normal
subjects. In addition to clinical diagnostic category, ligand retention will be evaluated
with respect to measures of symptom severity and cerebrospinal fluid levels of amyloid and
tau.
We found this trial at
1
site
3400 Spruce St
Philadelphia, Pennsylvania 19104
Philadelphia, Pennsylvania 19104
(215) 662-4000
Hospital of the University of Pennsylvania The Hospital of the University of Pennsylvania (HUP) is...
Click here to add this to my saved trials
